

37 – Acute Hepatitis

Speaker: David Thomas, MD




Acute Hepatitis

David L. Thomas, MD
Stanhope Bayne Jones Professor of Medicine
Johns Hopkins University
Chief of Infectious Diseases
Johns Hopkins School of Medicine

Disclosures of Financial Relationships with Relevant Commercial Interests

- Data and Safety Monitoring Board: Merck
- Advisory Board: Merck



48 year-old with jaundice

- 48 year old found minimally responsive and brought by friends to ED
 - 1 week malaise, chills, headaches, leg pain and weakness
- PMH – ETOH, IDU
- SH – homeless
- Baltimore for 20 years, previously Missouri

48 year-old with jaundice, con't

- T 39.1; BP 80/50; P 110; 95% 4L; sleepy
- Icteric, non-injected, no murmurs or lymphadenopathy
- Diffuse red maculopapular rash
- WBC 98,000 (79 P, 4 B, 5 My/Meta); Hb 7.7; Plt 31,000
- Creatinine 3.9; UA 1+pro; Bicarb 8; INR 2.5; Tbili 41 (direct 31); ALT/AST 146/213
- HCV Ab pos, HIV Ab neg

48 year old with jaundice

The cause of his illness is:

- A. Acute hepatitis A
- B. Babesia microti
- C. Ehrlichia chaffeensis
- D. Leptospira icterohaemorrhagiae
- E. SARS-CoV-2

37 – Acute Hepatitis

Speaker: David Thomas, MD

Leptospirosis

1. Exposure to fresh water (eg rafting in Hawaii or Costa Rico) OR rats (Baltimore)

Leptospirosis

2. Systemic findings (conjunctival suffusion, kidney, skin, muscle, lungs, liver)

ddx: liver and muscle: flu, adeno, EBV, HIV, malaria, Rickettsia/Ehrlichiosis, tularemia, TSS, coxsackie

Leptospirosis

3. Bilirubin fold change > ALT

Acute Hepatitis in Uganda

- 42 year old female has malaise and RUQ pain; she just returned from 2 months working at an IDP camp in north Uganda. She endorses tick and other 'bug' bites and swam in the Nile. 1st HAV vaccine 2 days before departure. Prior HBV vaccine series.
- Exam shows no fever, vitals are normal. RUQ tender. Mild icteric. ALT 1245 IU/ml; Hb 13.4 g/dl; TB 3.2 mg/dl; WBC 3.2k nl differential.

Acute hepatitis in Uganda

Which test result is most likely positive?

- A. Ebola PCR
- B. IgM anti-HEV
- C. IgM anti-HAV
- D. Schistosomiasis "liver" antigen
- E. 16S RNA for Rickettsial organism

1. Vaccination works vs immune globulin to prevent hepatitis A up to 14d after exposure


End Points	Per-Protocol Population		Modified Intention-to-Treat Population	
	Vaccine Group (N=568)	Immune Globulin Group (N=522)	Vaccine Group (N=740)	Immune Globulin Group (N=674)
Clinical				
Primary				
Any symptom plus IgM-positive and ALT ≥ twice ULN	25 (4.4)	17 (3.3)	26 (3.5)	18 (2.7)
Secondary				
Any symptom plus IgM-positive and ALT ≥ twice ULN or HAV RNA-positive on PCR	29 (5.1)	19 (3.6)	30 (4.1)	20 (3.0)
Jaundice plus IgM-positive and ALT ≥ twice ULN or HAV RNA-positive on PCR	18 (3.2)	12 (2.3)	19 (2.6)	12 (1.8)

Victor NEJM 2007

37 – Acute Hepatitis

Speaker: David Thomas, MD

2. There are HEV outbreaks, eg. North-Ugandan IDP Camp



Teshale CID 2010

3. Hepatitis E: Epidemiologic Clues

- Outbreaks – contaminated water in Asia/Africa
- Sporadic - undercooked meat (BOAR, deer, etc)
- Overseas travel typical
- USA: endemic rare, genotype 3, IgG serology positive far more than can be explained by cases - can be hard to interpret

4. Hepatitis E: Clinical Clues

- Fatalities in pregnant women
- Can be chronic in transplant (rarely in HIV)
- GBS and neurologic manifestations (vs other hep viruses); pancreatitis
- Diagnosis: RNA PCR; IgM anti-HEV
- Treatment: ribavirin for chronic

Acute Hepatitis at ID Week

- 42 year old homeless male approaches a group of ID fellows while attending ID Week in San Diego.
- One fellow noticed jaundice and suggested he seek medical testing. With what diagnosis was the fellow most concerned?

Acute hepatitis at ID week

Fellow worried about?

- A. HAV
- B. HBV
- C. Delta
- D. HCV
- E. HEV

1. Hepatitis A: Key Epidemiologic Clues

People, Places and Things (Foods)

Homelessness and Hepatitis A—San Diego County, 2016–2018

Corry M. Peck,^{1,2,3} Sarah S. Stovss,² Jessica M. Healy,² Megan G. Helmeiste,² Yulin Liu,² Sumathi Rameshchandra,¹ Monique A. Foster,¹ Annie Kee,² and Eric C. McDonald¹

¹Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia; ²County of San Diego Health and Human Services Agency and ³Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, San Diego, California; and Divisions of ⁴Toxoborne, Waterborne, and Environmental Diseases, and ⁵Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia

Morbidity and Mortality Weekly Report (MMWR)

DOI: 10.1093

Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men — New York City, January–August 2017

Weekly / September 22, 2017 / 66(37):999–1000

37 – Acute Hepatitis

Speaker: David Thomas, MD

1. Hepatitis A: Key Epidemiologic Clues — People, Places and Foods

Multistate Outbreak of Hepatitis A Linked to Frozen Strawberries – Current Case Count Map and Table

Posted December 16, 2010 2:00 PM ET



Case Count as of December 13, 2010
tropicalCARE
eat better. live better.

State	Case Count
Arkansas	1
California	1
Mississippi	12
New York	5
North Carolina	4
Oregon	1
Virginia	108
West Virginia	7
Wisconsin	3
Grand Total	143

Outbreak of hepatitis A in Hawaii linked to raw scallops

Posted August 19, 2010 3:00 PM ET

Outbreak

The Hawaii Department of Health (HDOH) is investigating an outbreak of hepatitis A in its state. For the latest case count and investigation findings, visit the HDOH outbreak investigation website. On August 13, 2010, HDOH identified one subject served at South Shore restaurants on the islands of Oahu and Kauai as a likely source of the ongoing outbreak.

CDC awarded a \$100,000 grant to HDOH to assist in the investigation. As the case, CDC is not aware of any hepatitis A virus infections in other states linked to the Hawaii outbreak. CDC continues to monitor for disease in other states.



2. Hepatitis A: Key Clinical Clues

- There are outbreaks all over the world now
- The **most common** cause of acute hepatitis in USA
- Clinical syndrome
 - **fulminant on HCV**
- relapsing: symptoms/jaundice recur <12 mo

3. Vaccination to Prevent Hepatitis A

- **Pre-exposure:** vaccinate
 - HOW: Inactivated vaccines USA (HAVRIX, VAQTA) (TWINRIX)
 - WHOM: HCV or HBV positive persons/chronic liver disease/homeless/MSM/PWID/Travelers/HIV pos/adoptee exposure
 - All children receive hepatitis A vaccine at age 1 since 2006
- **Post-exposure:** vaccinate (and possibly IG)
 - Unless > 40 years or immunosuppressed then IG is 'preferred'
 - Close exposure (sex or IDU partner) not casual (eg office worker)

Victor NEJM 2007; MMWR May 19, 2006 / 55(RR07) MMWR October 19, 2007 / 56(41);1080-1084

Vaccination works vs immune globulin to prevent hepatitis A up to 14d after exposure

End Points	Per-Protocol Population		Modified Intention-to-Treat Population [†]	
	Vaccine Group (N = 568)	Immune Globulin Group (N = 522)	Vaccine Group (N = 740)	Immune Globulin Group (N = 674)
Clinical				
Primary				
Any symptom plus IgM-positive and ALT ≥ twice ULN	25 (4.4)	17 (3.3)	26 (3.5)	18 (2.7)
Secondary				
Any symptom plus IgM-positive and ALT ≥ twice ULN or HAV RNA-positive on PCR [‡]	29 (5.1)	19 (3.6)	30 (4.1)	20 (3.0)
Jaundice plus IgM-positive and ALT ≥ twice ULN or HAV RNA-positive on PCR	18 (3.2)	12 (2.3)	19 (2.6)	12 (1.8)

Victor NEJM 2007

Acute Viral Hepatitis B Clues

- Most linked to sex, drugs, nosocomial
 - **Nosocomial** (fingerstick devices, etc)
 - Most transmissible (HBV>HCV>HIV)
- Clinical
 - Acute immune complex disease possible
 - Diagnose: IgM anti-core, HBsAg and HBV DNA
 - New infection vs reactivation (both can be IgM pos)

Acute Viral Hepatitis Delta will be with HBV

- HDV
 - HBV coinfection
 - Fulminant with acute HBV
 - HBV superinfection
 - Acute hepatitis in someone with chronic HBV
- Test for HDV RNA

37 – Acute Hepatitis

Speaker: David Thomas, MD

Acute Viral Hepatitis C clues

•HCV

- IDU link (hepatitis in Appalachia)
- HIV pos MSM
- Acute RNA pos but AB neg or pos
- 60-80% persist: more in men, HIV pos, African ancestry, INFL4 gene intact

Cox CID 2005

Hepatitis in a pilot

- 70 y/o pilot presents with 1 week of fever, diarrhea and sweats, then “collapses”
- Tooth extraction 1 month before, E. Shore of Maryland and extensive travel, chelation “treatment”
- T 38.1, 135/70, 85, 18, 97% on 2L; few small nodes, petechial rash on legs, neuro- WNL

Pilot Case History, con't

- Hct 33%, WBC 1.4 K (81% P 10% L), Plt 15,000
- Creat 2.8
- AST 495, ALT 159, Alk Phos 47, alb 2.6, TBR 0.8
- CPK 8477
- CXR: infiltrate LLL

Hepatitis in a pilot

What agent caused this illness?

- A. *Leptospira icterohaemorrhagiae*
- B. Hepatitis A
- C. EBV
- D. *Ehrlichia chaffeensis*
- E. Hepatitis G (GB virus C)

Hepatitis with bacterial infections

1. Think *Rickettsia*/*Ehrlichia* with exposure, low PMN, and especially low platelets

Hepatitis with bacterial infections

2. *Coxiella burnetti* and spirochetes (syphilis and lepto) also in ddx with liver, lung, renal, skin, CNS disease but tend to be cholestatic vs *Rickettsia*/*Ehrlichia*

37 – Acute Hepatitis

Speaker: David Thomas, MD

Hepatitis in pregnancy

2. HELLP

- HTN and can occur post partum
- Fibrinogen high vs. sepsis and AFLP

3. AFLP – severe and low glucose, inc INR, low fibrinogen (Swansea criteria)

Fulminant hepatitis

- 65 year old man with hx of jaundice. 2 weeks before finished amoxicillin/clavulanate acid for sinusitis. Hx of HTN on HCTZ and rosuvastatin. ETOH: 2 drinks per day.
- TB24; ALT 162 U/L; AST 97 U/L ALK P 235 U/L. IgM anti-HAV neg; IgM anti-HBc neg; HCV RNA neg. RUQ US neg.

Fulminant Hepatitis

Which of the following is the most likely cause of hepatitis:

- A. toxicity from amox/clav
- B. alcohol
- C. porphyria flare
- D. leptospirosis
- E. statin

Drug related liver toxicity

Amoxicillin/clavulanate is most common

- Cholestatic or mixed
- Often AFTER stopping
- 1/2500 Rx
- DRB1*1501
- clavulanate > amoxicillin

Rank	Agent	Year of FDA Approval	No. (N)	Major Phenotypes
1	Amoxicillin-clavulanate	1984	91 (10.1)	Cholestatic or mixed hepatitis
2	Isoniazid	1952	48 (5.3)	Acute hepatocellular hepatitis
3	Nitrofurantoin	1953	42 (4.7)	Acute or chronic hepatocellular hepatitis
4	TMP-SMZ	1973	31 (3.4)	Mixed hepatitis
5	Minocycline	1971	28 (3.1)	Acute or chronic hepatocellular hepatitis
6	Cefazolin	1973	20 (2.2)	Cholestatic hepatitis
7	Acithromycin	1991	18 (2.0)	Hepatocellular, mixed, or cholestatic hepatitis
8	Ciprofloxacin	1987	16 (1.8)	Hepatocellular, mixed, or cholestatic hepatitis
9	Levofloxacin	1996	13 (1.4)	Hepatocellular, mixed, or cholestatic hepatitis
10	Diclofenac	1988	12 (1.3)	Acute or chronic hepatocellular hepatitis
11	Phenytoin	1946	12 (1.3)	Hepatocellular or mixed hepatitis
12	Methyldopa	1962	11 (1.2)	Hepatocellular or mixed hepatitis
13	Azathioprine	1968	10 (1.1)	Cholestatic hepatitis

<http://livertox.nlm.nih.gov>; Hoofnagle NEJM 2019

Acute hepatitis in HIV

46 y/o HIV pos male, CD4+ lymphocyte 235/ml³, HIV RNA undetect; HBsAg pos; no symptoms on TDF/FTC/RAL. Liver enzymes increased from ALT of 46 to 1041 IU/L. TB was 2.3. He has a long history of various ART regimens. He is sexually active with other men.

Acute hepatitis in HIV

Which of the following is the most likely cause of hepatitis:

- A. toxicity from the RAL
- B. acute HCV infection
- C. IRIS
- D. resistant HBV
- E. HDV

37 – Acute Hepatitis

Speaker: David Thomas, MD

Recognize acute HCV in HIV POS MSM



World Hepatitis Day —
July 28, 2011

July 28, 2011, marks the first official World Hepatitis Day established by the World Health Organization

Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men — New York City, 2005–2010

Acute Hepatitis Summary

- Acute A: vaccine effective
- HEV: chronic in transplant and/or boar
- HIV: acute HCV in MSM
- Ehrlichial or rickettsial
- Find the leptospira case (jaundice > hepatitis)

Thanks and good luck on the test!

Questions:

Dave Thomas

- dthomas@jhmi.edu


BREAK
slides beyond this are for the presenter's records; not to be distributed or shown

Hepatitis in 2020: SARS-CoV-2

Table 2. Laboratory and radiographic findings of patients with COVID-19

	All patients (N = 788)
Leukocytes, $\times 10^9/L$	4.8 (3.8–6.0)
Neutrophils, $\times 10^9/L$	3.0 (2.2–4.0)
Lymphocytes, $\times 10^9/L$	1.2 (0.9–1.6)
$\geq 0.8 \times 10^9/L$	654 (83.0)
$< 0.8 \times 10^9/L$	134 (17.0)
Platelets, $\times 10^9/L$	181 (147–221)
$\geq 100 \times 10^9/L$	761 (96.6)
$< 100 \times 10^9/L$	27 (3.4)
Hemoglobin, g/L	138.0 (127.0–151.0)
International normalized ratio	1.02 (0.97–1.09)
Albumin, g/L	41.4 (38.3–43.8)
Alanine aminotransferase, U/L	21.1 (15.0–33.0)
Aspartate aminotransferase, U/L	25.0 (19.6–33.0)

Hao Am J Gastro 2020



Wang J Hepatol 2020

Case 6. Hepatitis in Pregnancy

- 24yo 33 wks gestation with nausea and vomiting and RUQ pain. Taking acetaminophen 1gm q6; has dog and bird; recent visit to mom in NC.
- T 37.2; BP 158/110; 2/6 SEM; RUQ tender; no rash.
- Plt 103K; Hct 26; WBC 6.6 10%L; PMN 82%; G 85; creat 0.6; ALT 225; AST 559; TB 1.4; CRP 15.8; PT WNL; fibrinogen NL.

37 – Acute Hepatitis

Speaker: David Thomas, MD


Case 4: Tired and jaundiced

- 27 year old male presents with fatigue and dark urine. Hx recent sexual exposures with other men.
- No fever, vitals normal. Mild icteric. ALT 1945 IU/ml; AST 1239 IU/ml; TB 4.2 mg/dl; WBC 3.2k nI diff.
- Total HAV pos; HAV IgM neg; HCV RNA neg; IgM anti-HBc pos; HBsAg pos; RPR neg; HIV 4th gen neg
- Ptr was tested and is HBsAg and anti-HBs neg

Question #4

- Which is easiest to justify medically?
- A. Repeat HBsAg and anti-HBs testing for partner
 - B. HBIG and HBV vaccine for partner
 - C. HBV vaccine for partner
 - D. Entecavir 0.5 mg/d for patient
 - E. TAF for partner

Diagnose acute HBV infection with IgM anti-HBc



2. No treatment indicated for acute HBV (unless fulminant)

3. Prevention by vaccine +/- HBIG

- HBsAg and anti-HBs screening of partners
- Tools: HBIG and/or HBV vaccine (USA)
 - Enderix, Recombivax, Hepelisav-B, Pediarix, Twinrix
- Post-exposure:
 - Vaccinated and anti-HBs >10 ever, done*
 - No hx vaccine and/or anti-HBs >10, HBIG and vaccinate

*may be exception for patients with immunosuppression like HIV or dialysis

Schillie MMWR 2018

3. Prevention by vaccine +/- HBIG con't

- Pre-exposure:
 - no vaccine hx – vaccinate
 - Vaccine hx no testing – test for anti-HBs, boost or revaccinate if neg, retest anti-HBs

MMWR 2018